(Reuters) – The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk (NYSE:)’s blockbuster weight-loss drug Wegovy.Here’s what Wall Street analysts say about the inclusion:

WHAT IT MEANS FOR PATIENTSThe potential for more aggressive price cuts would enable wider access to GLP-1 drugs – the same class of drugs as Ozempic and Wegovy – for people over the age of 65. Medicare prescription drug plans administered by private insurers, known as Part D, currently cannot cover drugs that are approved solely for obesity. Expanding coverage of anti-obesity drugs could enable more Americans to afford the new weight-loss medications. However, inclusion does not solve access or out-of-pocket costs issues for commercial and uninsured patients, BMO Capital Markets analysts said.

WHAT IT MEANS FOR SALES

Given that diabetes drugs, including Ozempic, are already heavily discounted and the negotiated cuts are based on the gross price rather than the discounted price, the impact of a negotiated price is expected to be small.

TD Cowen analysts estimate that about 45% of U.S. sales for Ozempic and Rybelsus each goes through Medicare Part D.

Wegovy, on the other hand, is eligible for coverage under Medicare only if the eligible overweight or obese patients have pre-existing heart conditions.This group constitutes around 3.6 million overweight or obese patients with heart conditions insured under the U.S. Medicare program, according to a study published last year by Kaiser Family Foundation. However, this was still a relatively small portion of obesity population in the U.S., according to TD Cowen analysts.

WHAT IT MEANS FOR PRICE

Ozempic has a list price of around $935 a month while Wegovy has a list price of around $1,350 a month, regardless of dosage, not taking any coupons and rebates into account.

The negotiated price cuts are based on the gross price and do not reflect after-market rebates or discounts the drugmakers had already been giving.

© Reuters. FILE PHOTO: Injection pens and boxes of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. REUTERS/Victoria Klesty/Illustration/File Photo

Novo has said it retains around 60% of Ozempic’s list price.

TD Cowen expects the negotiations to result in about 30% discount relative to the current average net price in 2027, adding that there was a wide range of possibilities on what the negotiations would be like with the incoming Trump administration.


Source link

Best Brokers

Unmatched trading fees, generous bonuses, top notch Regulation Frame.

T&Cs Apply

Risk disclosure: All investments involve a degree of risk of some kind. Trading financial derivative products comes with a high risk of losing money rapidly due to leverage.

Top-Tier Regulations. Unmatched Spreads and Commissions. Trading View is available.

T&Cs Apply

Financial Spread Trades and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84.7% of retail investor accounts lose money when trading CFDs with this provider.

Modern and Intuitive Interfaces, Solid Regulatory Frame, and excellent Trading Fees.

T&Cs Apply
Risk warning: Trading derivatives is highly speculative, carries an inherent risk of loss and is not suitable for all investors. Before trading, you are strongly advised to read and ensure that you understand the relevant risk disclosures and warnings.

Highly Regulated. Low Spreads and Commissions. Vast Account Options.

T&Cs Apply

Risk Warning: Trading derivatives carries significant risks. It is not suitable for all investors and if you are a professional client, you could lose substantially more than your initial investment.